This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Brain astrocytoma, helper endpoint
HLP_C3_ASTROCYTOMA
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
166 |
4. Check minimum number of eventsNone |
166 |
5. Include endpointsNone |
166 |
6. Filter based on genotype QC (FinnGen only) |
161 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Brain astrocytoma, helper endpoint
based on the number of shared cases.
Similar with more cases:
- Brain astrocytoma
- Brain astrocytoma, including Hilmo
- Brain glioblastoma and astrocytoma
- Malignant neoplasm of brain
- Malignant neoplasm of eye, brain and central nervous system
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 161 | 80 | 81 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 39.95 | 38.20 | 41.68 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 166
- Matched controls
- 1660
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
575.3
276.3
129
10
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
136.4
218.5
128
40
130
Kela drug reimbursment
Malignant tumour
129.5
215.0
135
54
N03AX14
ATC
levetiracetam; systemic
137.6
192.0
102
19
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
146.2
177.9
92
14
L01AX03
ATC
temozolomide; systemic
753.7
149.6
127
7
H02AB02
ATC
dexamethasone; systemic
49.7
149.5
124
93
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
48.6
147.8
124
95
A04AA02
ATC
granisetron; systemic, transdermal
51.5
141.1
95
42
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
106.2
123.0
65
10
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
42.5
105.5
70
28
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
73.8
103.5
58
12
WF002
NOMESCO Finland
Radical radiotherapy
37.4
99.5
69
31
C71.11
ICD-10 Finland
Malignant tumor of frontal lobe grade II glioma
792.4
90.4
81
*
N03AF02
ATC
oxcarbazepine; oral
29.6
82.0
61
32
9400/3-C71.1
ICD-O-3
Astrocytoma, NOS, of frontal lobe
+∞
68.6
61
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
23.0
67.2
55
35
R56.8
ICD-10 Finland
Other and unspecified convulsions
19.8
65.8
59
45
A03FA01
ATC
metoclopramide; systemic, rectal
13.6
65.3
112
220
WF003
NOMESCO Finland
Adjuvant radiotherapy
32.9
64.2
44
18
C71.10
ICD-10 Finland
Malignant tumor in frontal lobe without histology
163.0
61.9
62
6
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
190.7
61.8
61
5
9400/3-C71.9
ICD-O-3
Astrocytoma, NOS, of brain, NOS
+∞
58.9
53
*
XA800
NOMESCO Finland
Neuropsychological investigation
17.3
56.9
54
45
C71.21
ICD-10 Finland
Malignant tumor of temporal lobe grade II glioma
+∞
56.5
51
*
A04AA01
ATC
ondansetron; systemic, rectal
14.8
54.6
58
58
ZXC95
NOMESCO Finland
Use of surgical navigator
107.2
54.2
57
8
G40.9
ICD-10 Finland
Epilepsy, unspecified
27.1
52.1
38
18
AA1AD
NOMESCO Finland
CT of head and brain
10.4
51.7
111
269
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
278.7
43.1
42
*
Z51.5
ICD-10 Finland
Palliative care
13.7
42.4
45
44
XX3DW
NOMESCO Finland
Time consuming IT work
9.6
40.6
60
92
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.2
40.6
64
106
C71.20
ICD-10 Finland
Malignant tumor in temporal lobe without histology
+∞
39.1
36
*
N03AX18
ATC
lacosamide; systemic
78.6
33.7
37
6
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
7.4
33.3
64
129
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
106.2
32.1
34
*
9400/3-C71.2
ICD-O-3
Astrocytoma, NOS, of temporal lobe
+∞
31.2
29
*
C71.1
ICD-10 Finland
Malignant neoplasm: Frontal lobe
+∞
26.8
25
*
AAG00
NOMESCO Finland
Stereotactic intracranial biopsy
306.0
26.5
26
*
C71.12
ICD-10 Finland
Malignant tumor of frontal lobe grade III glioma
106.8
25.5
27
*
C71.2
ICD-10 Finland
Malignant neoplasm: Temporal lobe
292.2
25.4
25
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
49.6
24.5
29
7
ZXC40
NOMESCO Finland
Use of ultrasound
64.0
23.9
27
5
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
265.1
23.2
23
*
WX882
NOMESCO Finland
High dependency care
34.7
22.8
29
10
WX872
NOMESCO Finland
Intensive care
10.4
21.8
26
29
C71.90
ICD-10 Finland
Malignant tumor in unspecified localization in the brain without histology
+∞
20.2
19
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
36.4
19.9
25
8
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
17.0
19.5
31
22
D43.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Central nervous system, unspecified
79.5
19.2
21
*
C71.22
ICD-10 Finland
Malignant tumor of temporal lobe grade III glioma
+∞
19.1
18
*
N03AB02
ATC
phenytoin; systemic
37.8
18.5
23
7
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
200.5
17.9
18
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.0
17.6
98
437
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
35.9
17.5
22
7
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
56.4
17.4
20
*
C71.31
ICD-10 Finland
Malignant tumor of the parietal lobe grand II glioma
+∞
17.0
16
*
N03AG01
ATC
valproic acid; systemic, rectal
6.1
16.0
31
60
YX8VG
NOMESCO Finland
Stereotactic MRI exmaination with high intensity magnet for dose design of radiotherapy
94.2
15.9
17
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
175.9
15.8
16
*
N03AF01
ATC
carbamazepine; oral, rectal
7.9
15.7
23
33
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
62.7
15.1
17
*
A02BC02
ATC
pantoprazole; systemic
4.5
14.7
134
798
N05BA09
ATC
clobazam; oral
30.4
14.6
19
7
C71.23
ICD-10 Finland
Malignant tumor of temporal lobe grade IV glioma
+∞
13.7
13
*
C71.29
ICD-10 Finland
Malignant tumor in temporal lobe other or unspecified histology
151.9
13.7
14
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
18.7
13.4
20
12
ZX050
NOMESCO Finland
Stereotactic radiotherapy
54.5
13.1
15
*
N05CD08
ATC
midazolam; nasal, systemic
17.3
13.0
20
13
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
6.7
13.0
22
37
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
35.1
12.8
16
5
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
75.8
12.8
14
*
G40.10
ICD-10 Finland
Simple partial seizures
75.8
12.8
14
*
WZC30
NOMESCO Finland
Teaching
3.8
12.1
46
153
WX402
NOMESCO Finland
General anaesthesia
3.4
12.1
61
244
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
70.0
11.8
13
*
C71.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of brain
70.0
11.8
13
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.3
11.7
34
93
C71.13
ICD-10 Finland
Malignant tumor of frontal lobe grade IV glioma
+∞
11.6
11
*
C71.81
ICD-10 Finland
Overall malignant tumor of the brain grade II glioma
+∞
11.6
11
*
C71.01
ICD-10 Finland
Malignant tumor of cerebellum except lobes and ventricles grade II glioma
128.6
11.6
12
*
C71.19
ICD-10 Finland
Malignant tumor of frontal lobe other or unspecified histology
128.6
11.6
12
*
ZXM40
NOMESCO Finland
Use of fluorescent substance
128.6
11.6
12
*
C71.30
ICD-10 Finland
Malignant tumor in parietal lobe without histology
128.6
11.6
12
*
N03AX23
ATC
brivaracetam; systemic
128.6
11.6
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.2
10.8
58
239
H53.4
ICD-10 Finland
Visual field defects
13.3
10.6
18
15
AAA10
NOMESCO Finland
Biopsy through craniotomy
+∞
10.5
10
*
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
35.0
10.5
13
*
183
Kela drug reimbursment
Lamotrigin and topiramate
16.3
9.7
15
10
9400/3-C71.0
ICD-O-3
Astrocytoma, NOS, of cerebrum
+∞
9.5
9
*
C71.99
ICD-10 Finland
Malignant tumor in unspecified localization in the brain other or unspecified histology
39.0
9.1
11
*
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
39.0
9.1
11
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
94.7
8.5
9
*
H02AB09
ATC
hydrocortisone; systemic
10.3
8.5
16
17
H02AB04
ATC
methylprednisolone; systemic
3.7
8.4
30
94
N76
ICPC
Neoplasm nervous system unspecified
+∞
8.4
8
*
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
15.5
8.4
13
9
D43.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, unspecified
35.2
8.2
10
*
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
14.0
8.0
13
10
N02AA05
ATC
oxycodone; systemic
3.2
8.0
37
137
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
26.4
7.7
10
*
D43.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, infratentorial
83.7
7.5
8
*
C71.00
ICD-10 Finland
Malignant tumor of the cerebrum except lobes and ventricles without histology
83.7
7.5
8
*
C71.80
ICD-10 Finland
Overall malignant tumor of the brain without histology
+∞
7.3
7
*
9400/3-C71.3
ICD-O-3
Astrocytoma, NOS, of parietal lobe
+∞
7.3
7
*
R47.0
ICD-10 Finland
Dysphasia and aphasia
21.1
7.2
10
5
A28
ICPC
Limited function/disability NOS
3.3
6.9
28
95
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
10.0
6.9
13
14
AA1BD
NOMESCO Finland
Extensive CT of head and brain
8.4
6.8
14
18
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
13.0
6.7
11
9
N03AX09
ATC
lamotrigine; oral
3.9
6.5
20
56
G40.89
ICD-10 Finland
Other epilepsy
72.5
6.5
7
*
D33.00
ICD-10 Finland
Medial pilosytic astrocytoma of the cerebrum
72.5
6.5
7
*
ZSA00
NOMESCO Finland
Procedure related to previous procedure classified in chapter A
27.8
6.3
8
*
C71.82
ICD-10 Finland
Overall malignant tumor of the brain grade III glioma
+∞
6.3
6
*
C71.32
ICD-10 Finland
Malignant tumor of parietal lobe grade III glioma
+∞
6.3
6
*
C71.40
ICD-10 Finland
Malignant tumor of the occipital lobe without histology
+∞
6.3
6
*
AA5NK
NOMESCO Finland
Tractography within white matter of central nervous system
+∞
6.3
6
*
C71.91
ICD-10 Finland
Malignant tumor in unspecified location in the brain grade II glioma
+∞
6.3
6
*
2151
FHL
Resection, big brain
+∞
6.3
6
*
G40
ICD-10 Finland
Epilepsy
13.2
6.2
10
8
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Proper column names.
- Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV not working.
- No filters and sorters.
- Limited amount of endpoints with TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
D43.0 (45605364)
D43.0 (45605364)
Malignant tumor in frontal lobe without histology
C71.10 (2000501139)
C71.10 (2000501139)
Malignant tumor in temporal lobe without histology
C71.20 (2000501145)
C71.20 (2000501145)
Malignant tumor of frontal lobe grade II glioma
C71.11 (2000501140)
C71.11 (2000501140)
Malignant tumor of temporal lobe grade II glioma
C71.21 (2000501146)
C71.21 (2000501146)
Use of surgical navigator
ZXC95 (2001311381)
ZXC95 (2001311381)
Gas panel - Venous blood
24339-4 (3000991)
24339-4 (3000991)
Fractional oxyhemoglobin in Arterial blood
2714-4 (3014007)
2714-4 (3014007)
Neoplasm of uncertain or unknown behaviour: Central nervous system, unspecified
D43.9 (45561918)
D43.9 (45561918)
Epilepsy
G40 (45595935)
G40 (45595935)
Standard MRI examination of brain with high intensity magnet
AA1BG (2001300112)
AA1BG (2001300112)
Partial excision of intracranial lesion
AAB10 (2001300257)
AAB10 (2001300257)
Stereotactic intracranial radiotherapy
AAG50 (2001300312)
AAG50 (2001300312)
Adjuvant radiotherapy
WF003 (2001310702)
WF003 (2001310702)
General anesthesia, balanced
WX408 (2001310808)
WX408 (2001310808)
Use of ultrasound
ZXC40 (2001311369)
ZXC40 (2001311369)
More than three and less than five hours
ZXE20 (2001311408)
ZXE20 (2001311408)
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
182 (2001600181)
182 (2001600181)
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 (3006217)
2615-3 (3006217)
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 (3014218)
19230-2 (3014218)
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 (3016293)
1963-8 (3016293)
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 (3028653)
2030-5 (3028653)
Immunohistochemistry procedure
117617002 (4035726)
117617002 (4035726)
Body height measure
50373000 (4177340)
50373000 (4177340)
Body mass index
60621009 (4245997)
60621009 (4245997)
Malignant neoplasm of brain
C71 (45532930)
C71 (45532930)
Gas and Carbon monoxide and Electrolytes panel - Arterial blood
93685-6 (1001509)
93685-6 (1001509)
brivaracetam; oral, parenteral
N03AX23 (1588665)
N03AX23 (1588665)
Malignant tumor of frontal lobe grade III glioma
C71.12 (2000501141)
C71.12 (2000501141)
Malignant tumor of temporal lobe grade III glioma
C71.22 (2000501147)
C71.22 (2000501147)
Malignant tumor of the parietal lobe grand II glioma
C71.31 (2000501152)
C71.31 (2000501152)
Complex partial seizures with only alteration of consciousness
G40.20 (2000502139)
G40.20 (2000502139)
Extensive MRI examination of brain with high intensity magnet
AA1CG (2001300116)
AA1CG (2001300116)
Very extensive MRI examination of brain with high intensity magnet
AA1DG (2001300120)
AA1DG (2001300120)
Simple adjuvant cytostatic therapy
WB103 (2001310627)
WB103 (2001310627)
Scheduled procedure
ZXD10 (2001311387)
ZXD10 (2001311387)
Malignant tumour
130 (2001600128)
130 (2001600128)
phenytoin; oral, parenteral
N03AB02 (21604399)
N03AB02 (21604399)
carbamazepine; oral, rectal
N03AF01 (21604417)
N03AF01 (21604417)
Hemoglobin [Mass/volume] in Arterial blood
30313-1 (3002173)
30313-1 (3002173)
Chloride [Moles/volume] in Serum or Plasma
2075-0 (3014576)
2075-0 (3014576)
Gas panel - Arterial blood
24336-0 (3019060)
24336-0 (3019060)
Oncology Clinic/Center
261QX0200X (38004268)
261QX0200X (38004268)
Neurosurgery
14 (38004459)
14 (38004459)
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 (40762366)
59275-8 (40762366)
Malignant neoplasm: Temporal lobe
C71.2 (45600521)
C71.2 (45600521)
Other and unspecified convulsions
R56.8 (45602033)
R56.8 (45602033)
Complex partial epileptic seizure with secondary generalization
G40.22 (2000502141)
G40.22 (2000502141)
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
G40.29 (2000502142)
G40.29 (2000502142)
Infiltration anesthesia
WX110 (2001310767)
WX110 (2001310767)
General anaesthesia
WX402 (2001310806)
WX402 (2001310806)
Respiratory and circulatory monitoring
WX700 (2001310817)
WX700 (2001310817)
High dependency care
WX882 (2001310847)
WX882 (2001310847)
Epilepsy and comparable convulsive disorders
111 (2001600111)
111 (2001600111)
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 (2002330113)
SMOKING-2-3-0 (2002330113)
ondansetron; oral, parenteral, rectal
A04AA01 (21600493)
A04AA01 (21600493)
dexamethasone; oral, parenteral
H02AB02 (21602730)
H02AB02 (21602730)
oxcarbazepine; oral
N03AF02 (21604418)
N03AF02 (21604418)
levetiracetam; oral, parenteral
N03AX14 (21604436)
N03AX14 (21604436)
lacosamide; oral, parenteral
N03AX18 (21604440)
N03AX18 (21604440)
Emergency Room and Inpatient Visit
ERIP (262)
ERIP (262)
Blood group antibody screen [Presence] in Serum or Plasma
890-4 (3001079)
890-4 (3001079)
Base excess in Arterial blood by calculation
1925-7 (3003396)
1925-7 (3003396)
Bicarbonate [Moles/volume] in Arterial blood
1960-4 (3008152)
1960-4 (3008152)
Oxygen saturation in Arterial blood
2708-6 (3016502)
2708-6 (3016502)
aPTT in Platelet poor plasma by Coagulation assay
14979-9 (3018677)
14979-9 (3018677)
pH of Arterial blood
2744-1 (3019977)
2744-1 (3019977)
Oxygen [Partial pressure] in Arterial blood
2703-7 (3027801)
2703-7 (3027801)
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 (3027946)
2019-8 (3027946)
INR in Blood by Coagulation assay
34714-6 (3032080)
34714-6 (3032080)
Prothrombin time (PT) actual/Normal
5894-1 (3033658)
5894-1 (3033658)
Blood type and Crossmatch panel - Blood
34531-4 (3044640)
34531-4 (3044640)
Ophthalmology
18 (38004463)
18 (38004463)
Emergency Medicine
93 (38004510)
93 (38004510)
Tissue Pathology biopsy report
66121-5 (40768804)
66121-5 (40768804)
Astrocytoma, NOS, of brain, NOS
9400/3-C71.9 (44500170)
9400/3-C71.9 (44500170)
Astrocytoma, NOS, of temporal lobe
9400/3-C71.2 (44502304)
9400/3-C71.2 (44502304)
Astrocytoma, NOS, of frontal lobe
9400/3-C71.1 (44502797)
9400/3-C71.1 (44502797)
Malignant neoplasm: Frontal lobe
C71.1 (45557008)
C71.1 (45557008)
Epilepsy, unspecified
G40.9 (45562083)
G40.9 (45562083)
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
G40.2 (45591172)
G40.2 (45591172)
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 (46236098)
77397-8 (46236098)
Inpatient Hospital
21 (8717)
21 (8717)
Outpatient Hospital
22 (8756)
22 (8756)
Inpatient Visit
IP (9201)
IP (9201)
Neurology
13 (38004458)
13 (38004458)
Sodium [Moles/volume] in Serum or Plasma
2951-2 (3019550)
2951-2 (3019550)
Glucose [Moles/volume] in Serum or Plasma
14749-6 (3013826)
14749-6 (3013826)
Potassium [Moles/volume] in Serum or Plasma
2823-3 (3023103)
2823-3 (3023103)
Medical Oncology
90 (38004507)
90 (38004507)
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (3020460)
1988-5 (3020460)
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 (3021347)
1995-0 (3021347)
Creatinine [Moles/volume] in Serum or Plasma
14682-9 (3020564)
14682-9 (3020564)
Erythrocytes [#/volume] in Blood
26453-1 (3026361)
26453-1 (3026361)
MCH [Entitic mass]
28539-5 (3035941)
28539-5 (3035941)
Hemoglobin [Mass/volume] in Blood
718-7 (3000963)
718-7 (3000963)
Platelets [#/volume] in Blood
26515-7 (3007461)
26515-7 (3007461)
MCV [Entitic mean volume] in Red Blood Cells
30428-7 (3024731)
30428-7 (3024731)
Leukocytes [#/volume] in Blood
26464-8 (3010813)
26464-8 (3010813)
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 (3016431)
19072-8 (3016431)
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 (3009542)
20570-8 (3009542)
Outpatient Visit
OP (9202)
OP (9202)
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 (3003338)
28540-3 (3003338)
CBC panel - Blood by Automated count
58410-2 (40761511)
58410-2 (40761511)
Supplier / Service Provider
OMOP5117446 (33004)
OMOP5117446 (33004)
Laboratory Visit
OMOP4822461 (32036)
OMOP4822461 (32036)
pantoprazole; oral, parenteral
A02BC02 (21600097)
A02BC02 (21600097)
Emergency Room Visit
ER (9203)
ER (9203)
Pharmacy visit
OMOP4822462 (581458)
OMOP4822462 (581458)
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 (3006140)
14631-6 (3006140)
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 (3006923)
1742-6 (3006923)
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 (3007220)
2157-6 (3007220)
pH of Serum or Plasma
2753-2 (3018418)
2753-2 (3018418)
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 (40764999)
62238-1 (40764999)
Differential panel, method unspecified - Blood
69738-3 (42870588)
69738-3 (42870588)
Albumin [Mass/volume] in Serum or Plasma
1751-7 (3024561)
1751-7 (3024561)
Normoblasts [#/volume] in Blood
715-3 (3021589)
715-3 (3021589)
metoclopramide; oral, parenteral, rectal
A03FA01 (21600484)
A03FA01 (21600484)
Treatment plan or consultation
WZC00 (2001310885)
WZC00 (2001310885)
Case Management Agency
251B00000X (38004193)
251B00000X (38004193)
Office Visit
OMOP4822458 (581477)
OMOP4822458 (581477)
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 (3002385)
30385-9 (3002385)
12 lead EKG panel
34534-8 (3044889)
34534-8 (3044889)
Monocytes/Leukocytes in Blood
26485-3 (3019069)
26485-3 (3019069)
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 (3035995)
6768-6 (3035995)
Monocytes [#/volume] in Blood
26484-6 (3001604)
26484-6 (3001604)
Eosinophils/Leukocytes in Blood
26450-7 (3006504)
26450-7 (3006504)
Basophils/Leukocytes in Blood
30180-4 (3022096)
30180-4 (3022096)
paracetamol; oral, parenteral, rectal
N02BE01 (21604344)
N02BE01 (21604344)
Basophils [#/volume] in Blood
26444-0 (3006315)
26444-0 (3006315)
Lymphocytes/Leukocytes in Blood
26478-8 (3002030)
26478-8 (3002030)
Eosinophils [#/volume] in Blood
26449-9 (3013115)
26449-9 (3013115)
Lymphocytes [#/volume] in Blood
26474-7 (3019198)
26474-7 (3019198)
Neutrophils/Leukocytes in Blood
26511-6 (3018010)
26511-6 (3018010)
Neutrophils [#/volume] in Blood by Automated count
751-8 (3013650)
751-8 (3013650)
EKG study
11524-6 (3013512)
11524-6 (3013512)
Laceration/cut
S18 (2002000983)
S18 (2002000983)
Short blood count panel - Blood
55429-5 (40758558)
55429-5 (40758558)
ABO and Rh group [Type] in Blood
882-1 (3003694)
882-1 (3003694)
Internal Medicine
11 (38004456)
11 (38004456)
Teaching
WZC30 (2001310891)
WZC30 (2001310891)
hydrocortisone; oral, parenteral
H02AB09 (21602737)
H02AB09 (21602737)
Calcium [Moles/volume] in Serum or Plasma
2000-8 (3015377)
2000-8 (3015377)
Neuropsychological investigation
XA800 (2001300412)
XA800 (2001300412)
Physical Medicine And Rehabilitation
25 (38004468)
25 (38004468)
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
55
10
81.76
100.39
1.9
1.9
—
—
—
0
0
87
128
13.18
63.42
5.9
13.4
0.60
1.62
mmol/l
2.16
69
104
64
80
12.39
51.62
4.8
6.8
23.91
25.36
mmol/l
2.62
64
80
95
338
5.23
25.31
2.1
2.3
—
—
—
0
0
131
608
6.48
25.07
7.4
8.0
1.20
1.21
mmol/l
1.07
119
527
123
666
4.27
16.14
2.9
2.9
—
—
estimate
—
0
0
25
20
14.49
14.97
2.1
1.4
—
—
—
0
0
18
9
22.21
12.77
1.8
1.6
—
—
—
0
0
132
844
3.75
11.53
18.0
10.6
3.43
3.98
e9/l
2.79
114
742
23
48
5.40
10.85
1.9
1.3
68.06
17.64
e6/l
0.63
16
33
23
48
5.40
10.85
2.0
1.4
975.06
27.31
e6/l
0.49
16
35
82
418
2.90
10.33
9.3
3.6
2.38
2.35
mmol/l
1.62
77
381
89
540
2.40
7.09
4.5
5.2
36.96
36.82
g/l
0.08
84
517
113
1402
0.39
6.81
3.4
4.4
4.91
4.70
mmol/l
1.32
103
1333
113
1398
0.40
6.56
3.4
4.4
1.40
1.41
mmol/l
0.13
102
1324
10
9
11.72
5.88
1.0
1.2
—
—
—
0
0
117
1414
0.42
5.79
3.5
4.8
3.04
2.83
mmol/l
1.73
105
1340
110
1327
0.49
4.20
3.1
3.7
1.35
1.28
mmol/l
0.43
99
1245
89
1135
0.53
3.79
3.4
3.7
—
—
—
0
0
106
1278
0.53
3.62
3.9
5.1
36.15
38.01
mmol/mol
2.65
95
1224
10
22
4.77
3.49
1.1
1.2
—
—
—
0
0
10
22
4.77
3.49
1.1
1.2
—
—
—
0
0
7
10
7.25
3.40
1.1
1.0
—
—
—
0
0
26
124
2.30
3.36
8.3
7.8
—
—
—
0
0
111
1309
0.54
3.24
4.2
4.2
5.49
5.77
mmol/l
3.02
104
1226
15
56
2.85
3.15
1.6
1.5
—
—
—
0
0
69
480
1.75
3.02
2.7
3.1
13.33
29.45
ng/l
1.64
46
277
15
59
2.70
2.88
1.1
1.4
—
—
—
0
0
6
10
6.18
2.72
1.0
1.3
—
—
—
0
0
8
20
4.15
2.60
1.1
1.1
—
—
—
0
0
0
60
0.00
2.30
0.0
1.1
—
—
—
0
0
0
60
0.00
2.30
0.0
1.1
—
—
—
0
0
6
16
3.85
1.95
1.0
1.8
—
—
—
0
0
20
342
0.53
1.95
3.6
4.3
4.82
9.35
mg/mmol
0.60
12
220
0
53
0.00
1.91
0.0
1.4
—
10.59
—
0
10
151
1586
0.47
1.81
40.7
20.6
135.83
138.73
g/l
1.79
151
1575
151
1585
0.48
1.76
39.6
20.5
4.51
4.61
e12/l
1.81
151
1557
151
1585
0.48
1.76
40.4
20.9
40.44
41.37
%
2.24
151
1572
151
1584
0.48
1.70
39.7
20.5
90.69
90.32
fl
0.52
151
1573
10
41
2.53
1.67
1.4
1.7
—
—
—
0
0
151
1583
0.49
1.65
39.5
20.6
246.44
252.15
e9/l
0.31
151
1561
10
42
2.47
1.65
1.5
1.8
—
—
—
0
0
19
107
1.88
1.63
1.2
1.2
—
27.06
—
0
7
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
14
3.65
1.62
1.0
1.3
—
—
—
0
0
31
203
1.65
1.61
1.8
1.6
—
—
—
0
0
6
20
3.07
1.59
1.3
2.5
19.20
17.02
%
—
6
20
0
42
0.00
1.55
0.0
1.5
—
—
—
0
0
0
45
0.00
1.52
0.0
1.3
—
82.17
—
0
6
151
1406
1.82
1.40
25.4
14.3
3.90
3.94
mmol/l
1.55
151
1375
151
1407
1.81
1.38
26.1
14.2
139.23
139.72
mmol/l
1.30
151
1381
0
38
0.00
1.36
0.0
1.5
—
—
—
0
0
31
213
1.56
1.33
2.8
2.6
4.28
2.62
e6/l
0.25
16
92
35
248
1.52
1.31
2.1
2.9
28.27
703.13
ng/l
0.82
15
153
28
396
0.65
1.28
1.5
1.7
—
—
—
0
0
29
403
0.66
1.21
3.1
3.5
0.00
0.00
estimate
—
10
151
120
1308
0.70
1.18
4.3
5.1
1.57
1.75
mu/l
1.52
113
1230
5
111
0.43
1.18
1.2
1.3
—
—
—
0
0
0
33
0.00
1.17
0.0
1.2
—
—
—
0
0
7
35
2.04
1.01
1.0
1.5
—
—
—
0
0
15
232
0.61
1.01
2.2
2.8
0.61
0.77
ug/l
—
8
126
31
227
1.45
1.00
2.8
2.6
0.57
0.65
e6/l
0.15
16
106
61
723
0.75
0.97
2.5
3.1
89.21
92.79
ug/l
0.09
55
692
9
156
0.55
0.93
3.7
2.3
30.22
27.09
u/l
—
9
128
63
740
0.76
0.92
3.3
3.5
0.00
0.00
estimate
-0.00
12
156
21
145
1.51
0.90
1.6
1.6
—
—
—
0
0
65
751
0.78
0.81
3.3
3.6
0.00
0.00
estimate
-0.00
12
146
46
374
1.32
0.80
2.5
2.7
0.14
0.18
e6/l
0.26
32
270
21
149
1.47
0.80
1.9
1.6
—
—
—
0
0
8
48
1.70
0.80
3.0
2.1
3.34
3.64
g/l
—
8
48
11
172
0.61
0.79
1.1
2.1
—
—
—
0
0
65
747
0.79
0.76
3.1
3.5
0.00
0.00
estimate
-0.00
12
156
52
612
0.78
0.74
2.4
2.5
75.01
74.01
nmol/l
0.10
46
564
5
25
2.03
0.73
1.6
1.4
—
—
—
0
0
36
442
0.76
0.70
3.2
2.8
0.00
0.01
estimate
—
10
129
22
286
0.73
0.63
2.5
4.0
21.49
22.14
%
—
10
116
8
49
1.66
0.63
2.8
2.0
200.38
178.65
%
—
8
49
0
20
0.00
0.61
0.0
1.5
—
8.68
—
0
20
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
0
22
0.00
0.60
0.0
1.7
—
—
—
0
0
0
22
0.00
0.60
0.0
1.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.5
—
—
—
0
0
26
324
0.77
0.57
1.7
2.3
—
—
—
0
0
149
1436
1.37
0.54
23.7
13.4
19.59
21.91
mg/l
0.55
141
1148
142
1360
1.31
0.54
23.6
12.3
97.45
91.73
ml/min/173m2
3.28
133
1226
50
572
0.82
0.52
3.3
3.2
0.00
0.00
estimate
-0.00
11
137
29
352
0.79
0.52
1.8
2.4
—
—
—
0
0
7
46
1.54
0.49
2.1
1.6
0.16
0.39
nmol/l
—
7
41
21
261
0.78
0.45
1.4
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
7
101
0.68
0.41
1.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
101
1070
0.86
0.40
3.8
4.4
14.23
14.58
pmol/l
0.73
94
1003
121
1262
0.85
0.37
32.6
16.5
13.34
13.34
%
0.01
121
1251
52
466
1.17
0.37
2.8
3.0
—
—
—
0
0
12
90
1.36
0.37
1.4
1.6
—
—
—
0
0
29
328
0.86
0.26
2.8
3.4
1.02
1.02
kg/l
0.66
19
217
5
40
1.26
0.22
1.2
1.4
—
—
—
0
0
5
40
1.26
0.22
1.2
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
0.60
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
5.5
—
98.64
—
0
12
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
3.17
—
0
12
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.8
—
15.00
—
0
13
0
13
0.00
0.21
0.0
2.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
147.58
—
0
13
18
207
0.85
0.20
1.3
2.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
8.14
—
0
14
19
166
1.16
0.19
1.8
1.6
1267.80
1184.94
nmol/l
—
10
127
5
68
0.73
0.17
1.6
1.9
42.60
41.90
u/l
—
5
61
6
76
0.78
0.16
1.0
1.1
1.43
1.48
g/l
—
6
76
6
77
0.77
0.16
1.0
1.1
0.78
0.90
g/l
—
6
77
50
530
0.92
0.16
1.7
1.9
93.19
101.00
pmol/l
0.61
27
269
9
80
1.13
0.15
1.7
2.1
8.77
6.25
ug/l
—
9
71
7
85
0.82
0.15
3.9
3.6
67.29
79.31
ng/l
—
7
76
150
1516
0.89
0.11
20.7
10.9
29.21
28.34
u/l
0.21
150
1494
30
320
0.92
0.11
2.0
2.0
1.84
2.71
mg/l
3.15
24
279
31
330
0.93
0.10
1.5
1.8
1.19
1.22
mg/l
0.02
22
252
5
43
1.17
0.10
1.6
1.2
—
—
—
0
0
5
60
0.83
0.08
1.2
1.6
—
—
—
0
0
6
73
0.82
0.08
1.3
3.1
25.33
24.26
mmol/l
—
6
73
13
118
1.11
0.07
3.1
3.4
—
—
—
0
0
9
84
1.08
0.07
1.3
1.3
—
—
—
0
0
36
346
1.05
0.06
1.4
1.5
17.37
20.43
nmol/l
0.75
31
303
11
120
0.91
0.05
1.6
3.6
6.05
5.72
kpa
0.62
11
115
17
179
0.94
0.03
2.1
2.9
10.42
7.39
umol/l
0.18
12
162
151
1516
0.96
0.00
30.4
15.9
69.56
75.41
umol/l
3.57
151
1500
15
145
1.04
0.00
4.7
4.0
24.78
32.38
%
—
9
92
0
7
0.00
0.00
0.0
1.1
—
0.28
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
63.24
—
0
9
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
53
0.94
-0.00
2.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
1436.88
—
0
8
0
6
0.00
-0.00
0.0
1.3
—
19.50
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
191.40
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
-0.00
1.2
1.1
—
3.90
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
9.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: HLP_C3_ASTROCYTOMA – Brain astrocytoma, helper endpoint
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).